FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

-	-		_				_		•	_	-	 	-	_
٧	95	hii	nat	ัดท	D	C.	20	154	9					

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average bu	urden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					01 56	CuOI	1 30(11) OF THE	investine	III CO	прапу Аст	01 194	+0						
l	nd Address of oumi Mol		2. Issuer Name and Ticker or Trading Symbol Monte Rosa Therapeutics, Inc. [GLUE]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner							
(Last) 2855 SA		3. Date of Earliest Transaction (Month/Day/Year) 06/28/2021								Officer (give title Other (specify below)								
(Street) MENLO		4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City) (State) (Zip)																		
		٦	Table I - Non	-Deriva	ative S	Secu	urities Ac	quired,	Dis	posed o	f, or	Ben	eficially	Owned				
1. Title of S	2. Transac Date (Month/Da	Day/Year) Execution Day		ecution Date,	Code (Transaction Di Code (Instr.		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			5. Amount Securities Beneficially Following Reported		Form:	Direct Indirect It. 4)	7. Nature of ndirect Beneficial Ownership			
								Code	v	Amount		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common	06/28/2	3/2021		С		2,715,968		A	(1)	2,715,968				See Note				
Common Stock 0					3/2021			С		3,257,328		A	(1)	5,973,296				See Note 2 ⁽²⁾
Common Stock 06/2						3/2021		С		669,002		A	(1)	6,642,298		I		See Note 2 ⁽²⁾
Common Stock 06/28						.021		P		1,050,000		A	\$19	7,692,298				See Note
			Table II - I				ities Acqı warrants							wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code (Instr.				6. Date Exercis Expiration Dat (Month/Day/Ye		e Secui ar) Deriv		Title and Amount ecurities Underlyin erivative Security nstr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitic Benefici Owned Followir Reporte	ve es ially ng d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi (Instr. 4)
				Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	- 11	Amount or Number of Shares		Transac (Instr. 4)			
Series A-2 convertible preferred stock	(1)	06/28/2021		С			9,588,725	(1)		(1)	Com	imon ock	2,715,968	(1)	0	0		See Note 2 ⁽²⁾
Series B convertible preferred	(1)	06/28/2021		С			11,500,000	(1)		(1)		imon ock	3,257,328	(1)	0		I	See Note 2 ⁽²⁾

Explanation of Responses:

(1)

1. Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

2,361,912

2. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

(1)

(1)

Stock

Remarks:

Series C

preferred Stock

/s/ Sasha Keough, attorney-infact

** Signature of Reporting Person

669,002

(1)

06/30/2021

Date

See Note

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/28/2021

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

С

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.